A Tour around Cystitis
(Date of publication 18 June 2004) Statistically, at least 20% of
women reading this will be familiar with the symptoms of cystitis: a need to
urinate frequently, pain in the lower abdomen, discomfort during urination and
blood in the urine. Bacteria are the most frequent culprit - cystitis is the
single most common bacterial infection in humans - but mycobacteria, fungi and
bacteria may also be responsible, and there are non-infectious causes such as
radiation, chemicals and autoimmune reactions. Patient information from
Harvard Medical School explains why women, especially those
who are sexually active, are more susceptible than men, and incorporates a
section on prevention. Suggestions include drinking plenty of fluids, urinating
after intercourse and avoiding feminine hygiene products which may act as
irritants.
Similar ground is covered in slightly more detail by the
netdoctor site. Here, the importance of completely emptying
the bladder is stressed, which is bad news for bibliophiles; sitting on the
toilet and leaning forward to read makes total voiding very difficult.
By far the most common causative agent - responsible for around 90% of
infections - is Escherichia coli, a normal commensal of the gut.
Consulting an
online
textbook of bacteriology reveals that this Gram-negative facultative
anaerobe is something of a microbial athlete, capable of colonising the human
bowel within 40 hours of birth. There are more than 700 serotypes but only a
few strains are pathogenic, causing urinary tract infections, neonatal
meningitis and gastroenteritis. These strains utilise surface antigens that
form projections, and are known as adhesins, to colonise the bladder. The
cellular structure is clearly shown in this
transmission electron micrograph of a single cell and this
three-dimensional view of a colony.
The second
most common cause of urinary tract infections in young, sexually active women
in both Europe and the United States is
Staphylococcus saprophyticus, which can be
identified by its intense pigment production and resistance to novobiocin.
As we have already seen, cystitis is usually treated with a short
course of antibiotics such as trimethoprim/sulfamethoxazole. However, new
regulations introduced in the US last February aim to reduce the development of
drug resistance by more targeted use of narrow-spectrum antibiotics for
specific infections such as uncomplicated cystitis. The subject is treated very
comprehensively in a
US Department of Health newsletter for primary care
physicians, which also provides a lot of background information about the
condition itself.
The major complication of cystitis is
pyelonephritis: infection of the upper urinary tract and
one or both kidneys. Onset is usually sudden, with chills, fever, lower back
pain, nausea and vomiting. Hospitalisation and intravenous antibiotics may be
required if the patient is severely ill, and the choice of antibiotic is
determined by laboratory sensitivity studies.
Therapy usually comprises a two or three week course, the
primary objective being permanent eradication of bacteria from the urinary
tract). Untreated or recurrent kidney infection can lead to chronic
pyelonephritis, with scarring of the kidneys and permanent kidney damage.
To digress for a moment,
interstitial cystitis (IC) is a condition that produces
similar symptoms to the bacterial infection described above but has notable
differences - it is chronic, no pathogens can be detected in the urine, and the
cause is unknown. Normally, the epithelium of the bladder is protected from
toxins in the urine by a glycoaminoglycan (GAG) protein layer, but in IC this
layer breaks down and allows toxins to irritate the bladder wall. For a more
detailed hi-tech explanation, try the video
here. The condition is poorly understood, but it may be an
autoimmune disease and studies suggest there is also a hereditary risk factor.
Other theories are that it is caused by ischaemia, an undetectable pathogen, or
a deficiency of GAG in the epithelial cells.
Over time, stiffening and
scarring of the bladder wall may occur. Characteristic IC lesions are
glomerulations (pinpoint bleeding following recurrent irritation - see the
photograph
here) and Hunner's ulcers (ulcerative patches surrounded by
mucosal congestion - see an example
here).
Treatment is aimed at relieving symptoms and most patients
benefit from a combination of therapies. These include procedures such as
bladder distension and instillation, transcutaneous electrical nerve
stimulation (TENS), oral drugs, and surgery, such as bladder augmentation to
increase its capacity. The difficulties of treatment and assessing patient
response are well illustrated in
this
lengthy article.
Returning to bacterial cystitis, this is one area
where traditional remedies have been found to have a basis in fact. For many
years, cranberry juice was thought to reduce bacterial infections of the
bladder and recent studies have shown that it inhibits the adherence of E.
coli to the cells of the epithelial lining. A
1994 trial demonstrated that the juice decreases the
incidence of bacteria and pus in the urine of elderly women, and in 2001 a
Finnish
study found that it reduces the occurrence of cystitis in patients with a
history of urinary tract infections, attributing this effect to the presence of
high levels of proanthocyanidins. However, a note of caution is sounded in a
message at the bottom of the
IrishHealth site, where a heartfelt plea implores sufferers
"do not actually drink it during an attack of cystitis. It is far too acidic
and adds to the burning sensation!"
|
This medical briefing was written by
Derrick Garwood, a Freelance Medical Writer and Editor, and first published, on
this same date, in the series of InPharm Tours at
InPharm.com. It is
reproduced here with permission from the publishers.
The links presented here were accurate at the time of
publication, but remember that information on the Web has a tendancy to change
without notice! |
Disclaimer
OnePharm Internet
excludes any warranty, express or implied, as to the quality, accuracy,
timeliness, completeness or fitness for a particular purpose of this briefing.
OnePharm Internet will not be liable for any claims, penalties, losses,
damages, costs, or expenses arising from the use of or inability to use this
briefing or from any unauthorised access to or alteration of the Briefing.
OnePharm Internet makes no warranty that the contents of this briefing are
compatible with all computer systems and browsers.
|